Wearable glucose tracker Ultrahuman raises €14.8M in Series B funding

The funds raised will be used for geographical expansion and to improve their biomarker technology.
By Sara Mageit
06:29 am
Share

Ultrahuman

India and US-based metabolic fitness platform, Ultrahuman has announced it has raised €14.8 million ($17.5m), to build on its goal to help people suffering from metabolic health disorders.

The Series B funding came from a range of London-based investors including, Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund.

Marquee founders and angel investors also participated including Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra and Roman Saini.

WHY IT MATTERS

The company has been developing their Ultrahuman Cyborg, a wearable technology that helps people optimise their exercise and nutrition based on glucose biomarkers.

The technology uses glucose biomarkers to reveal how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their microbiome diversity, stress levels, time of the day and food ingredient quality.

Over a billion people in the world suffer from a metabolic health disorder which contributes to approximately 85% of all chronic diseases in the world.

Ultrahuman aims to help people understand how food and exercise affects their metabolic health, consequently enabling people to make informed choices about what they eat and their activity levels. The approach is a geography and diet agnostic way to help people eat and exercise better. 

The company also intends to launch across Europe in early 2022.

THE LARGER CONTEXT

In Dubai, the GluCare Integrated Diabetes Center, has become the first healthcare provider outside of the United States to be awarded full URAC accreditation in Remote Patient Monitoring (RPM), for its diabetic patients.

In related news, Abbott's FreeStyle Libre 2 app has achieved FDA clearance to help users manage diabetes. The new system can be used with Apple iPhones and lets users check their glucose without needing a reader.

ON THE RECORD

Ultrahuman founder and CEO Mohit Kumar, said: “Biomarkers will change how the fitness and the healthcare industry works. By being able to continuously monitor their biomarkers like glucose, users can not only avoid chronic diseases but make lifestyle changes that help them improve their fitness levels for longevity and performance."

Share